Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)
ID: RFA-DA-25-053Type: BOTH
Overview

Topic

Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: STTRPhase: BOTHYear: 2024

Topic Link

https://www.sbir.gov/node/2504579

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-053.html
Timeline
  1. 1
    Release Jan 29, 2024 12:00 AM
  2. 2
    Open Jun 25, 2024 12:00 AM
  3. 3
    Next Submission Due Jul 25, 2024 12:00 AM
  4. 4
    Close Jul 26, 2024 12:00 AM
Description

The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the topic of "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)".

This solicitation aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy to prevent or treat substance use disorders (SUDs). The goal is to streamline and enhance decision-making in drug discovery efforts for SUDs using AI/ML technologies.

The research objectives include identifying and validating disease targets, screening potential compounds, developing assays to test candidate compounds, synthesizing novel compounds, and conducting in vitro and in vivo studies to assess efficacy and toxicity.

This Small Business Technology Transfer (STTR) program is a phased program, with Phase I focused on establishing technical merit and feasibility, and Phase II aimed at advancing the technology towards commercialization. Successful projects are expected to attract strategic partners or investors for ultimate commercialization.

Phase I and Fast Track applications are accepted, with Fast Track allowing Phase I and Phase II applications to be submitted and reviewed together for expedited award decisions. Milestones and deliverables must be clearly defined for Fast Track applications.

The solicitation is currently open, with a release date of January 29, 2024, an open date of June 25, 2024, and a close date of July 26, 2024. More information can be found on the grants.gov website.

Files
No associated files provided.
Similar Opportunities
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis surrounding OUD/StUD is a significant issue, with over 100,000 overdose deaths reported in a one-year period. The goal of this solicitation is to offer new medical products that can monitor, diagnose, and treat patients suffering from these disorders. The solicitation is open to small business companies that have developed or are developing FDA-regulated products for different indications and are interested in demonstrating their potential application in the OUD/StUD space. The research and development activities may fall into two areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The proposed projects should aim to address the needs of patients suffering from OUD/StUD and may include activities such as target identification, lead optimization, preclinical studies, formulation development, and clinical trials. The funding for these projects will be provided through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding available. The application due dates are August 15, 2023, February 14, 2024, August 13, 2024, and February 14, 2025. For more information and to apply, interested parties can visit the grants.gov website or the solicitation agency URL provided.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus are pharmacotherapeutics (small molecules, biologics, natural products, etc.) and medical therapeutic and diagnostic devices (imaging technologies, therapeutic devices, diagnostic assays, etc.). The projects proposed should aim to establish technical feasibility, commercial potential, and the quality of performance of the small business awardee organization. The funding opportunity includes Phase I, Phase II, Fast Track, and Direct to Phase II applications. The deadline for applications is February 15, 2025. For more information and to apply, visit the grants.gov website or the solicitation agency URL provided.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Fast-Track (Phase I/Phase II) applications, with a focus on establishing technical feasibility and commercial potential. The application due date is March 13th, 2024, with subsequent due dates in 2025 and 2026. More information can be found on the grants.gov website.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Phase II applications, including Fast-Track applications that combine both phases. The deadline for submission is March 14, 2026. For more information, visit the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html).
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by Opioid and/or Stimulants use Disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus for this solicitation are pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The research topics may include the development of new medications, longer-acting formulations, advanced drug delivery systems, biomarkers, imaging technologies, therapeutic devices, in vitro diagnostic assays, and digital therapeutics. The projects proposed under this solicitation may fall under Phase I, Phase II, Fast Track, or Direct to Phase II categories. The funding opportunity is open until February 15, 2025. For more information and to apply, visit the grants.gov website or the National Institutes of Health's solicitation agency URL.